Amicogen, Inc. (KOSDAQ:092040)
3,615.00
+5.00 (0.14%)
Jun 19, 2025, 3:30 PM KST
Amicogen Revenue
Amicogen had revenue of 10.82B KRW in the quarter ending March 31, 2025, a decrease of -68.34%. This brings the company's revenue in the last twelve months to 150.25B, down -3.61% year-over-year. In the year 2024, Amicogen had annual revenue of 173.60B with 8.57% growth.
Revenue (ttm)
150.25B
Revenue Growth
-3.61%
P/S Ratio
1.32
Revenue / Employee
667.77M
Employees
225
Market Cap
197.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 173.60B | 13.70B | 8.57% |
Dec 31, 2023 | 159.90B | 15.61B | 10.82% |
Dec 31, 2022 | 144.30B | 19.41B | 15.55% |
Dec 31, 2021 | 124.88B | 9.02B | 7.79% |
Dec 31, 2020 | 115.86B | 675.18M | 0.59% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,898.69B |
Celltrion | 3,662.23B |
ALTEOGEN | 151.65B |
Yuhan | 2,114.76B |
SK Biopharmaceuticals | 578.00B |
HLB Co., Ltd. | 74.64B |
Peptron | 4.30B |
PharmaResearch | 392.31B |